



ANTICHOLINERGIC DRUGS

INTRODUCTION

- Drugs which **block** *Cholinoreceptors* have important clinical effects, some of which are of great clinical value
- **Muscarinic and Nicotinic**
 - M1, M2, M3, M4 and M5
 - NN and NM



CHOLINERGIC RECEPTORS

- **Conventionally** – Anticholinergic drugs are those which block actions of Ach autonomic effectors and in the CNS exerted through **Muscarinic** receptors
- Nicotinic (**NN**) antagonists – ganglion blockers
- **N_M** Blockers – neuromuscular blockers
 - **Atropine** is the prototype – many **synthetic** and **semi synthetics** are available now
 - All are **competitive antagonists**



CLASSIFICATION – ANTICHOLINERGIC DRUGS

- I. **Natural:** Atropine and Hyoscine (scopolamine)
- II. **Semisynthetic derivatives:** Homatropine, Atropine methonitrate, Hyoscine butylbromide, Ipratropium bromide, Tiotropium bromide
- III. **Synthetic Compounds:**
 - (a) **Mydriatics:** Cyclopentolate and Tropicamide
 - (b) **Antisecretory-antispasmodics:**
 - Quaternary ammonium compounds:**
Propantheline, Oxyphenonium, Clidinium, Pipenzolate methylbromide, Glycopyrrolate, Isopropamide
 - Tertiary amines:** Dicyclomine, Valethamate, Pirenzepine
 - (c) **Vasoselective:** Oxybutynin, Flvoxate, Tolterodine
 - (d) **Antiparkinsonian:** Trihexyphenidyl (Benzhexol), Procyclidine, Biperiden
- IV. **Additionally** – TCAs, Phenothiazines and Antihistaminics




ATROPINE AS PROTOTYPE

- **Atropine (hyoscyamine)** is found in the plant *Atropa belladonna*, or **deadly nightshade**
- Also in *Datura stramonium*, also known as jimsonweed (Jamestown weed) or **thorn apple**
- **Scopolamine (hyoscine)** occurs in *Hyoscyamus niger*



ATROPINE - CHEMISTRY

- **Atropine:** Ester of **tropic acid (aromatic acid)** + **tropine**
- **Scopolamine:** Ester of **tropic acid (aromatic acid)** + **scopine**
- Chemically tropine and scopine are closely similar
- Most of the actions of both are similar



The structure of atropine (oxygen at [1] is missing) or scopolamine (oxygen present). In homatropine, the hydroxymethyl at [2] is replaced by a hydroxyl group, and the oxygen at [1] is absent.

ATROPINE – MECHANISM OF ACTION

- Atropine causes reversible (surmountable) blockade of cholinomimetic actions at muscarinic receptors
 - blockade by a small dose of atropine can be overcome by a larger concentration of acetylcholine or equivalent muscarinic agonist
- Atropine is highly selective for muscarinic receptors
- Does not distinguish between the M1, M2, and M3
- Some quaternary amine antimuscarinic agents have significant ganglion-blocking actions



ATROPINE - PHARMACOKINETICS

○ Absorption:

- The natural alkaloids and most tertiary antimuscarinic drugs are well absorbed from the gut and conjunctiva – some even over the skin (scopolamine)
- Penetrates cornea freely
- Quaternary ones – only upto 30%

○ Distribution:

- Atropine and the other tertiary agents are widely distributed in the body
- **Scopolamine** is rapidly and fully distributed into the **central nervous system** where it has greater effects than most other **antimuscarinic** drugs
- Quaternary derivatives are poorly taken up by the brain


○ Metabolism:

- Atropine is metabolized in liver by conjugation and 60% excretes unchanged in urine
- Effects disappear quickly within 2 Hrs **except eye**
- Hyoscine is more completely metabolized

○ Preparations: Atropine IM or IV; Hyoscine – Oral/IM/transdermal



PHARMACOLOGICAL ACTIONS - CNS

- **Overall CNS stimulant**
 - At low dose - Atropine has only peripheral effects and minimal stimulant effect on CNS – **low entry**
 - **Scopolamine** has more marked central effects (**depressant**) – amnesia and drowsiness.
 - Atropine **stimulates** many medullary centres – **vagal, respiratory** and **vasomotor**.
 - **Depresses** vestibular excitation – antimotion sickness property.
 - **Blocks** basal ganglia cholinergic over activity – **blocks tremor, rigidity**
- 

PHARMACOLOGICAL ACTIONS OF ATROPINE - CVS

- **Heart:** Moderate and high doses: **TACHYCARDIA** (Blockade of M2 receptor on SA node - vagal tone decreases HR)
- Higher the vagal tone – more Bradycardia - in young adults
- AVN – Atropine abbreviates refractory period of AVN– facilitates AV conduction rate (reduced PR interval in ECG)
- **IM/SC injection initially** – transient **BRADYCARDIA** – may be due to inhibition of prejunctional postsynaptic M1 autoreceptor inhibition (not due to stimulation of vagal centre)
- Evidenced by Pirenzepine (selective M1 blocker) injection does not cross BBB
- **BP: No consistent effect** – tachycardia and VMC stimulation – raises BP; but histamine release and direct vasodilator action counteract

PHARMACOLOGICAL ACTIONS, ATROPINE-EYE

- **MYDRIASIS**
- Topical atropine and other **antimuscarinic** drugs - results in unopposed sympathetic dilator activity and **mydriasis**
- **Cycloplegia** and **abolition of light reflex** - desirable in Ophthalmology
- Photophobia and blurring of near vision
- **IOP** rises: hazardous in narrow angle glaucoma
- **Dry Eye**: Not desirable






Fig. 8.1: Autonomic control of pupil (A); and site of action of mydriatics (B) and miotics (C)

ATROPINE ON SMOOTH MUSCLE

- **Respiratory:** Bronchodilatation and reduction in airway resistance – COPD and asthma patients
 - **Urinary:** Relaxation of ureter & bladder – urinary retention in older males with BHP
 - Sometimes useful in increasing bladder capacity and controlling detrusor hyperreflexia - neurogenic bladder/enuresis
 - **Visceral SM:** Relaxation – mediated by **M3** blockade
 - Tone and amplitude of contraction of Stomach and Intestine reduced
 - Passage of chyme reduced – **CONSTIPATION** and relieve of **SPASM**
 - But, **less peristalsis suppression** – **ENS**
 - More effective to exogenous ACh administration
- 

ATROPINE ON GLANDS

- **Decreases** salivary, sweat, tracheobronchial and lachrymal secretions (**M₃** blockade)
 - dryness of mouth, dry skin and conjunctiva and difficulty in talking and swallowing
 - **Stomach (M₁): decreases** acid, pepsin and mucus secretions – **pH** of gastric contents **may increase** – in empty stomach
 - But **pH not interfered** – **as also** decreases **bicarbonate (HCO₃)** secretion – **Higher doses required to cause acidity**
 - Atropine is less efficacious than H₂ blockers
 - No effect on intestinal and pancreatic secretion
 - No effect on bile production
- 

PHARMACOLOGICAL ACTIONS OF ATROPINE – CONTD.

- **Temperature:** Increases – decrease sweating + stimulation of temperature regulating centre in hypothalamus
- **Local anaesthetic action:** on cornea
- **Sensitivity of organs** – Saliva, sweat, bronchial secretion > smooth muscle of intestine and bladder > gastric gland and smooth muscle






**Semi synthetics and
Synthetics** ATROPINE SUBSTITUTES

ATROPINE SUBSTITUTES

- **Semisynthetic:** Mydriatic, antispasmodic, bronchodilator etc.
- **Synthetic:** Mydriatic, antisecretory-antispasmodic (quaternary - antisecretory or tertiary), vasoselective, antiparkinsonian
- Quaternary compounds (for peripheral action only in GIT):
 - Incomplete oral absorption
 - Poor CNS and eye penetration
 - Slow elimination – longer acting
 - Higher Nicotinic blocking property – postural hypotension and impotence
 - Neuromuscular blockade at higher doses



INDIVIDUAL DRUGS – ATROPINE SUBSTITUTES - SEMISYNTHETIC

- **Hyoscine Butylbromide**: Oesophageal and GIT spastic conditions – Buscopan – Oral/IM
 - **Atropine methonitrate**: Abdominal colics and hypercidity – Oral/IM
 - **Ipratropium Bromide**: Selective action on Bronchial SM - dilatation
 - Does not alter volume and consistency of respiratory secretion
 - Enhanced **mucocilliary clearance** (contrast to Atropine)
 - Slowly acting (slow onset and late peak) Bronchodilator - 1-2 Hrs (prophylactic use) – contrast to sympathomimetics – 4-6 Hrs
 - Acts mainly on larger Central airways (contrast to sympathomimetics)
 - More effective in COPD than Asthma
 - **ADRs**: cough, bad taste and nervousness – rare systemic effects
 - **Tiotropium bromide**: Ipratropium congener – longer acting and more M₁/M₃ selective
- 

ATROPINE SUBSTITUTES – QUATERNARY

- **Propantheline**: Used in peptic ulcer and gastritis – reduces gastric acid secretion – mild side effects – not popular now
- **Oxyphenonium**: Peptic ulcer and gastric hypermotility
- **Clinidium**: Nervous dyspepsia, gastritis, IBS, colic etc.
- **Pipenzolate methyl bromide**: Flatulent dyspepsia, infantile colics
- **Glycopyrrolate**: IM/oral – rapid acting without central effects – preanaesthetic medication



ATROPINE SUBSTITUTES – TERTIARY AMINES



- **Dicyclomine , valethamate and Pirenzepine**
- **Dicyclomine:** Direct SM relaxant and antispasmodic – weak anticholinergic
 - Lesser side effects than Atropine
 - Also antiemetic – morning sickness
 - Atropine toxicity in infants (not recommended below 6 months)
 - Dysmenorrhoea and IBS
- **Valethmate:** Dilatation of Cervix in delayed labour (visceral antispasmodic)
- **Pirenzepine:** Selective M1 antagonist – no action on M2 and M3 (no atropinic side effects)
 - Decreases gastric acid secretion - promotes ulcer healing
 - Less popular now



ATROPINE SUBSTITUTES

- VASICOSELECTIVE – CONTD.



○ **Oxybutynin:**

- Specific selectivity for receptors in Urinary bladder and salivary gland (M1/M3)
- Additional smooth muscle relaxation property and local anaesthetic property
- Uses
 - Detrusor instability – urinary frequency and incontinence
 - Spina bifida and nocturnal enuresis
 - Involuntary voiding in patients with neurologic disease - children with meningomyelocele
 - Bladder surgery - urologic surgery
 - Dose: 5 mg BD/tds or local instillation

○ **Tolterodine** – M3 selective—overactive bladder with urinary urgency

○ **Flavoxate** – similar to Oxybutynin

- ### ○ **Drotaverine:** Non anticholinergic smooth muscle relaxant – inhibition of PDE-4 - elevation of cAMP/cGMP – **sm relaxation**
- Renal colic, biliary colic, IBS, uterine spasms etc.
 - No anticholinergic side effects - Dose: 40 – 80 mg tds



ATROPINE SUBSTITUTES

- MYDRIATICS

- **Atropine:** Slow and long lasting
 - Onset of action: 30 – 40 minutes
 - Cycloplegia: 1 – 3 Hours
 - Duration of action: 7 – 10 days




Fig. 6.1: Autonomic control of pupil size and site of action of mydriatics (B) and miotics (C)

	Homatropine	Cyclopentolate	Tropicamide
Potency	10 times less	Potent	Less reliable
Onset of action	45 – 60 min	30 – 60 min	20 – 40 min
Duration of action	1 – 3 days and 1-2 days	1 day	3 – 6 Hours
Children use	Unsatisfactory cycloplegia	Behavioural abnormality	Mental and mood changes

ATROPINE: THERAPEUTIC USES - ANTISECRETORY

1. **Preanaesthetic medication:** atropine, hyoscine and glycopyrrolate etc.

- **Defn.:** Refers to use of drugs before anaesthesia to make it more pleasant and safe
- Irritant GA (ether) – salivary and tracheobronchial secretion
- **To reduce secretions** and also halothane induced ventricular arrhythmia (in vagal slowing down)
- To prevent laryngospasm – increased respiratory secretions cause reflex laryngospasm

2. **Peptic ulcer:** Fasting and neurogenic phase only – Gastric phase not reduced – **Not popular anymore**

3. **Pulmonary embolism:** reduces reflex pulmonary secretions




ATROPINE: THERAPEUTIC USES - ANTISPASMODIC


1. Intestinal and renal colic and abdominal cramps
– not in biliary colic
2. Diarrhoea (nervous and drug induced) –
Lomotil --- not in infective ones
3. Spastic constipation, IBS
4. Pylorospasm, gastric hypermotility, gastritis,
nervous dyspepsia etc.
5. Urinary frequency and urgency and nocturnal
enuresis (children) - ???
6. Dysmenorrhoea



ATROPINE: THERAPEUTIC USES – BRONCHIAL ASTHMA, ASTHMATIC BRONCHITIS AND COPD

- **Reflex vagal activity** – bronchoconstriction and increased secretion – in bronchitis and COPD – lesser in asthma
 - **Oral Atropine** – bronchodilatation
 - **Disadvantages:** dry up secretions in RT – inspissations and plugging in bronchioles – collapse – plus decreased mucocilliary clearance
 - Inhaled **Ipratropium Br** – does not decrease secretions and impair mucociliary clearance - useful in bronchitis and COPD
 - For regular prophylaxis – not to terminate acute attack
- 

ANTICHOLINERGICS -MYDRIATIC AND CYCLOPLEGIC - OPTHALMIC USES

- Used as eye drop or ointment:
 - **Diagnostic:** Atropine 1% ointment is used
 - Measurement of refractive error – mydriasis and cycloplegia
 - Preferred ones: Homatropine, Tropicamide and cyclopentolate – shorter action
 - However – no cycloplegia in children by newer ones
 - Atropine 1% ointment still preferred in children below 5 yrs
 - **Ophthalmic examination** of retina – fundoscopy (shorter acting preferred)
 - **Therapeutic :**
 - For resting eye: Iritis, iridocyclitis, keratitis, corneal ulcer etc.
 - Alternating with miotics (prevention of synechia)
- 

USES OF ANTICHOLINERGICS – CONTD.

- **CVS:** Myocardial Infarction, Digitalis toxicity – to counteract reflex vagal bradycardia and partial heart block
 - **Parkinsonism:** Mild cases of parkinsonism (early cases), Drug induced Parkinsonism and adjunct to Levodopa
 - **Motion sickness:**
 - Hyoscine (scopolamine) is the drug used – Oral, injection and transdermal patch
 - 0.2 mg orally given as prophylaxis before journey – lasts 4-6 hours – transdermal preparations
 - Not effective in other type of vomiting
 - **Twilight sleep** and **maniacal states:** **Hyoscine** - sedation and amnesia – lie detector
 - Atropine: Antidote for Anti-ChE & Mushroom poisoning, and to block Muscarinic effects of Neostigmine, Cobra envenomation
- 

ANTICHOLINERGIC - ADRs

- Commonly occurring but of non serious type
- Mydriasis and cycloplegia – using as antisecretory or Preanaesthetic medication
- **Belladonna Poisoning:** Drug overdose and consumption of seeds of berries of belladonna/datura
 - Symptoms:
 - Dry mouth, difficulty in swallowing and talking
 - Dry, flushed and hot skin (face & neck), fever, decreased bowel sound, dilated pupil, photophobia, difficulty in micturation
 - Excitement, psychotic behavior, delirium and hallucinations
 - Hypotension, weak and rapid pulse, respiratory depression and cardiovascular collapse
 - Convulsions and coma



BELLADONA POISONING - TREATMENT

- **Diagnosis:** Methacholine 5 mg or Neostigmine 1 mg SC – no muscarinic effects
- **Treatment:**
 - Gastric lavage in case of ingestion – tannic acid
 - Dark Room and cold sponging and ice bags
 - Physostigmine 1–3 mg SC or IV
 - Maintenance of blood volume, assisted respiration and Diazepam to control convulsions
 - Other supportive measures



ANTICHOLINERGIC - CONTRAINDICATIONS


- **Glaucoma** – Narrow angle (Precipitation of angle closure)
- **BHP** – urinary retention
- **Acid peptic ulcer diseases** (Non-selective ones) – precipitation of symptoms





DRUGS ACTING ON GANGLIONS

DRUGS ACTING ON AUTONOMIC GANGLIA

- **ACh** is excitatory neurotransmitter - parasympathetic and sympathetic
 - Drugs which inhibit **synthesis or release** – interfere with **ganglionic transmission**
 - **N_N** mediate rapid depolarization of ganglion cells
 - also present are M₁ & M₂, adrenergic, dopaminergic, amino acid, peptidergic receptors - slow – mediate slowly developing and longer lasting effects
 - Released from preganglionic cholinergic terminals – but by themselves
 - **One transmitter – one cell junction ... Over simplification**
- 

GANGLION STIMULANTS AND BLOCKERS

○ **Ganglion stimulants:**

- **Selective agonists:** Nicotine (small dose), Lobeline, DMPP, TMA and Varenicline
- **Non-selective:** Acetylcholine, carbachol, Pilocarpine, Anticholinesterases

○ **Ganglion Blockers:**

- Competitive blockers:
 - **Quaternary compounds:** Hexamethonium, Pentolinium
 - **Secondary/tertiary:** Mecamylamine, Pempidine
 - Monosulfonium compound:
Trimethaphancamsulfonate
- Persistent depolarizers: Nicotine (large dose) and Anticholinesterases (large doses)



NICOTINE



- Source – alkaloid in *Nicotiana tabacum*
- Action – stimulation of Para symp and symp ganglia via N_N and N_M receptors at low dose
 - Large doses – persistent depolarization
- **Only Indication** – short term nicotine replacement in tobacco abstinent Subjects



PHARMACOTHERAPY OF SMOKING CESSATION

- Difficult to quit - Nicotine dependence – counseling and motivation
- Aim of treatment:
 - To reduce the craving for satisfying (reward) effects of nicotine
 - To suppress the physical withdrawal symptoms
- Drugs: Nicotine replacement, Partial agonists of $\alpha 4\beta 2$ Nicotinic receptors (Varenicline) and antidepressants (Bupropion)
- Nicotine transdermal: once daily on the hip/abdomen/chest/upper arm – suppresses nicotine withdrawal but craving only partially (10, 20, 30 cm² patches)
 - Also nicotine chewing gum - alternative of patches (NULIFE 1, 2, 4 mg chewing gums)
 - ADRs of nicotine replacement: headache, dyspepsia, abdominal cramps, loose motion, flu like symptoms etc



VARENICLINE


- Partial agonists of $\alpha 4\beta 2$ NR receptor
- MOA: Reinforcing effects mediated by $\alpha 4\beta 2$ NR – nucleus accumbens and mesolimbic areas
 - Normally, activation of $\alpha 4\beta 2$ NR by nicotine – induces DA release – satisfaction/reward and reinforcing effect
 - PA activity of varenicline - nicotine substitution, but blocks reward effects of smoking
 - Reduce craving and withdrawal symptoms
 - Comparable to nicotine replacement and Bupropion
- **ADRs:** Mood changes, irrational behaviour, appetite and taste disturbances, sleep disorder and agitation – suicidal thoughts
- **Bupropion:** atypical antidepressant – discussed elsewhere
- **Ganglion blockers** – no clinical use anymore



SUMMARY

- Atropine and its Pharmacological Effects
 - Therapeutic uses of Atropine
 - Mechanism of Mydriasis and Cycloplegia
- Names of Atropine Substitutes with their Uses
 - Details of Atropine Substitutes – Ipratropium bromide, Dicyclomine, Oxybutynin
- Treatment of Atropine Poisoning
- Names of Ganglion Stimulants and Blockers Drugs – antismoking drugs (short note)





THANK YOU

